Search
Kansas Paid Clinical Trials
A listing of 886 clinical trials in Kansas actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
565 - 576 of 886
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Kansas is currently home to 886 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Wichita, Kansas City, Overland Park and Topeka. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
Recruiting
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Central Care Cancer Center, Garden City, Kansas
Conditions: Extensive-stage Small-cell Lung Cancer
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
02/07/2025
Locations: Home-based telemedicine, Topeka, Kansas
Conditions: Chronic Granulomatous Disease (CGD)
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Recruiting
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/06/2025
Locations: Aton Health, Leawood, Kansas
Conditions: Lung Cancer Diagnosis
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Recruiting
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial).
The study contains of 5 arms:
NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data.
* Treatment Arm (Group 1)
* Active Control Arm (Group 2)
* Crossover Arm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University of Kansas Medical Center (KUMC), Kansas City, Kansas
Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients with CtDNA-positive, Resected Stage II (high Risk) and Stage III Colorectal Cancer
Recruiting
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University of Kansas Cancer Center, Westwood, Kansas
Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Different Doses of Naronapride Vs. Placebo in Gastroparesis
Recruiting
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/04/2025
Locations: Dr Falk Investigational Site, Topeka, Kansas
Conditions: Gastroparesis
A Randomized Multicenter Study for Isolated Skin Vasculitis
Recruiting
Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis, Henoch-Schönlein Purpura
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
Recruiting
Pancreatic cancer is a deadly disease and will be the second leading cause of cancer related death behind lung cancer by 2030. Over 62,000 people are diagnosed each year in the United States with about 90% succumbing to the disease within 5 years. In the metastatic setting, NALIRIFOX, FOLFIRINOX and nab-paclitaxel-gemcitabine are standard treatment options in patients with good performance status (Eastern Cooperative Oncology Group \[ECOG\] 0/1). All three combinations have shown a survival adva... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Conditions: Pancreatic Cancer
SELUTION 4 De Novo Small Vessel IDE Trial
Recruiting
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA.
The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Cardiovascular Research Institute of Kansas, Wichita, Kansas
Conditions: Coronary Artery Disease
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Recruiting
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: The University of Kansas Cancer Center, Westwood, Kansas
Conditions: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)
Recruiting
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled.
The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Site 122, Overland Park, Kansas
Conditions: Chronic Spontaneous Urticaria
Health-Related Physical Fitness Level from Smartwatches
Recruiting
Health-related physical fitness (HRPF) has demonstrated high clinical relevance, and its level is associated with the ability to perform activities of daily living with vigor and a lower risk of chronic disease. Consequently, exercise prescription guidelines recommend improving HRPF as a focus for prevention and rehabilitation programs. Measuring and tracking HRPF often requires specialized equipment and personnel, which are expensive and less applicable to the general population. Wearables may... Read More
Gender:
ALL
Ages:
Between 20 years and 60 years
Trial Updated:
01/30/2025
Locations: Kansas State Univeristy, Manhattan, Kansas
Conditions: Exercise Capacity, Flexibility, Strength and Endurance